Company research
Shattuck Labs, Inc.
CIK 1680367Updated Sep 24, 2026
SecuritySTTK · NASDAQ · equity
Name history
Shattuck Labs, Inc. · through Aug 14, 2026
STTK price & chart
Loading TradingView…
NASDAQ:STTK on TradingView ↗About the company
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www. ShattuckLabs.com.
In the news
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering ↗
Recent filings
SCHEDULE 13G/A filing
S-8 filing
Results of Operations and Financial Condition
Items 2.02
10-Q filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 91,026,000Source | 91,049,000Source | 159,564,000Source | 205,324,000Source |
| Property, Plant and Equipment, NetUSD | 6,114,000Source | 9,812,000Source | 13,804,000Source | 17,671,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 54,192,000Source | 57,387,000Source | 125,626,000Source | 47,379,000Source |
| Assets, CurrentUSD | 82,475,000Source | 79,215,000Source | 143,220,000Source | 184,584,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,410,000Source | 6,228,000Source | 12,595,000Source | 23,304,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,337,000Source | 1,843,000Source | 2,271,000Source | 2,635,000Source |
| Other Assets, NoncurrentUSD | 1,437,000Source | 2,022,000Source | 2,540,000Source | 3,069,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,636,000Source | 11,423,000Source | 14,859,000Source | 29,167,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 7,000Source | 5,000Source | 5,000Source | 5,000Source |
| Additional Paid in CapitalUSD | 512,906,000Source | 461,339,000Source | 451,006,000Source | 396,041,000Source |
| Retained Earnings (Accumulated Deficit)USD | -430,529,000Source | -381,720,000Source | -306,310,000Source | -219,012,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 6,000Source | 2,000Source | 4,000Source | -877,000Source |
| Stockholders' Equity Attributable to ParentUSD | 82,390,000Source | 79,626,000Source | 144,705,000Source | 176,157,000Source |
| Liabilities and EquityUSD | 91,026,000Source | 91,049,000Source | 159,564,000Source | 205,324,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 7,052,000Source | 8,917,000Source | 11,453,000Source | 24,965,000Source |
| Operating Lease, Liability, CurrentUSD | 837,000Source | 900,000Source | 796,000Source | 701,000Source |
| Accounts Payable, CurrentUSD | 2,101,000Source | 2,419,000Source | 1,587,000Source | 7,170,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,584,000Source | 2,506,000Source | 3,406,000Source | 4,202,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 78,100,000Source | 73,000,000Source | 130,600,000Source | 161,300,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,700,000Source | 3,800,000Source | 4,000,000Source | 3,100,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,995,000Source | 9,546,000Source | 6,939,000Source | 6,462,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -318,000Source | 832,000Source | -5,629,000Source | -2,842,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -39,882,000Source | -60,515,000Source | -81,228,000Source | -94,498,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -7,887,000Source | -8,511,000Source | 110,859,000Source | 49,438,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 71,000Source | 59,000Source | 407,000Source | 11,614,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 65,000Source | 451,000Source | 53,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 44,574,000Source | 787,000Source | 48,616,000Source | 171,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,195,000Source | -68,239,000Source | 78,247,000Source | -44,889,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 54,192,000Source | 57,387,000Source | 125,626,000Source | 47,379,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,995,000Source | 9,546,000Source | 6,939,000Source | 6,462,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 78,100,000Source | 73,000,000Source | 130,600,000Source | 161,300,000Source |
| DepreciationUSD | 3,688,000Source | 3,829,000Source | 4,042,000Source | 3,073,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -303,000Source | -704,000Source |
| General and Administrative ExpenseUSD | 17,235,000Source | 19,077,000Source | 19,304,000Source | 21,082,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 2,703,000Source | 5,174,000Source | 4,669,000Source | 1,592,000Source |
| Net Income (Loss) Attributable to ParentUSD | -48,809,000Source | -75,410,000Source | -87,298,000Source | -101,945,000Source |
| Nonoperating Income (Expense)USD | 2,699,000Source | 5,157,000Source | 4,659,000Source | 1,384,000Source |
| Operating ExpensesUSD | 52,508,000Source | 86,288,000Source | 93,614,000Source | 103,981,000Source |
| Operating Lease, ExpenseUSD | 800,000Source | 800,000Source | 800,000Source | 800,000Source |
| Other Nonoperating Income (Expense)USD | -4,000Source | -17,000Source | -10,000Source | -208,000Source |
| Proceeds from Issuance of Common StockUSD | 44,475,000Source | — | 48,170,000Source | — |
| Restructuring CostsUSD | — | 900,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 1,000,000Source | 5,721,000Source | 1,657,000Source | 652,000Source |
| Operating Income (Loss)USD | -51,508,000Source | -80,567,000Source | -91,957,000Source | -103,329,000Source |
| Other Nonoperating Income (Expense)USD | -4,000Source | -17,000Source | -10,000Source | -208,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -48,809,000Source | -75,410,000Source | -87,298,000Source | -101,945,000Source |
| Earnings Per Share, BasicUSD per share | -0.7Source | -1.49Source | -2.05Source | -2.41Source |
| Earnings Per Share, DilutedUSD per share | -0.7Source | -1.49Source | -2.05Source | -2.41Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 69,584,937Source | 50,758,290Source | 42,600,190Source | 42,378,895Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 69,584,937Source | 50,758,290Source | 42,600,190Source | 42,378,895Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 17,235,000Source | 19,077,000Source | 19,304,000Source | 21,082,000Source |
| Investment Income, InterestUSD | 2,703,000Source | 5,174,000Source | 4,669,000Source | 1,592,000Source |
| Nonoperating Income (Expense)USD | 2,699,000Source | 5,157,000Source | 4,659,000Source | 1,384,000Source |
| Operating ExpensesUSD | 52,508,000Source | 86,288,000Source | 93,614,000Source | 103,981,000Source |
| Operating Lease, ExpenseUSD | 800,000Source | 800,000Source | 800,000Source | 800,000Source |
| Research and Development ExpenseUSD | 35,273,000Source | 67,211,000Source | 74,310,000Source | 82,899,000Source |
| Restructuring CostsUSD | — | 900,000Source | — | — |
Filing attachments
d163713dex41.htm · 8-K · 2026-06-11
EX-4.1 3 d163713dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: [•], 2026 Shattuck Labs, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase fr…
Read attachment ↗d120796dex991.htm · 8-K · 2026-06-09
EX-99.1 2 d120796dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Shattuck Labs Announces Phase 1 Results for SL-325 Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1 mg/kg and higher ────────────────────────────────────────────────────────────────────────────────────────────────────── Well tolerated with a favorable safety profile consistent …
Read attachment ↗d120796dex992.htm · 8-K · 2026-06-09
EX-99.2 3 d120796dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update AUSTIN, Texas and DURHAM, N.C., June 9, 2026 (GLOBE NEWSWIRE) - Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, t…
Read attachment ↗